Skip to main content

Quantification of Circulating Cell Free Mitochondrial DNA in Extracellular Vesicles with PicoGreen™ in Liquid Biopsies: Fast Assessment of Disease/Trauma Severity.

Marcatti M, Saada J, Okereke I, Wade CE, Bossmann SH, Motamedi M, Szczesny B

Publication: Cells (2021) • Vol 10PMID: 33917426View on PubMed

Purpose

This paper compared the levels of mitochondrial DNA (mtDNA) and nuclear DNA (nuDNA) in serum from patients with adenocarcinoma, benign growths, or traumatic brain injury to serum from healthy controls. The levels of mtDNA and nuDNA were also compared between serum before and after DNAse treatment and between serum, isolated exosomes, and the supernatant. The authors also quantified the DNA yield by fluorometry and compared results with real-time PCR amplification of mtDNA and nuDNA.

Conclusion

The DNA concentration was 2- to 3-fold higher and more consistent among primer sets when quantified using mtDNA primers rather than nuDNA primers, which indicated primer-dependent variability in concentration. In each case, DNA concentration as determined by real-time PCR did not differ among groups when classified by adenocarcinoma stage but was sometimes higher in serum from patients with adenocarcinoma than healthy controls and was dependent on the gene used for quantification. DNA concentration as measured by fluorometry was higher in serum from patients with adenocarcinoma than in serum from volunteers and resembled the DNA yield as determined by real-time PCR using mitochondrial gene-specific primers. Most of the DNA in serum (90%) remained after incubation of serum with DNAse, indicating that the DNA is potentially protected by being localized in exosomes. Greater than 90% of the mtDNA found in serum was found in the exosome pellet, confirming the association of the serum mtDNA with exosomes, but very little mtDNA was found in the supernatant. A much smaller amount of nuclear DNA was present and, like the mtDNA, was mostly associated with the exosomes. Mitochondrial gene levels in serum were higher in both mild and severe traumatic brain injury than healthy controls, but for nuclear DNA, only the difference between healthy controls and severe traumatic brain injury was significant. Importantly, the DNA concentration as measured by PicoGreen mirrored the results for mtDNA and was lower in serum from healthy volunteers compared to serum from patients with mild or severe traumatic brain injury.

Studies (1)

Purpose

This study compared the levels of mitochondrial DNA (mtDNA) and nuclear DNA (nuDNA) in serum from patients with adenocarcinoma, benign growths, or traumatic brain injury to serum from healthy controls. The levels of mtDNA and nuDNA were also compared between serum before and after DNAse treatment and between serum, isolated exosomes, and the supernatant. The authors also quantified the DNA yield by fluorometry and compared results with real-time PCR amplification of mtDNA and nuDNA. Frozen serum from patients with stage I (21 patients), II (12 patients), III (13 patients), and IV (11 patients) lung adenocarcinoma (26 males and 31 females, aged 33-92 years), 20 patients with benign growth (11 males and 9 females, aged 42-73 years), and 20 healthy controls were obtained from the Lung Cancer Biospecimen Resource Network. To confirm the results would be valid in fresh serum, the authors obtained blood from 12 adenocarcinoma patients and four control patients. To confirm if elevated mtDNA concentrations reflected changes in DNA concentration quantified by fluorometry, serum was obtained from 20 healthy volunteers and 53 patients with traumatic brain injury (33 severe and 20 mild). DNA was isolated from serum using the DNeasy Blood & Tissue Kit. Levels of the mitochondrial cytochrome B (mtCYTB), NADH dehydrogenase subunit I (mtNAD1), and cyclooxygenase (mtCOXIII) and nuclear sirtuin 1 (nuSIRT1) and β-actin (nuACTB) genes were quantified by real-time PCR. Total DNA was also quantified in the fresh serum specimens using the fluorometry-based Quanti-iT PicoGreen Kit. EVs were isolated from fresh serum using the Total Exosome Isolation Kit.

Summary of Findings

The DNA concentration was 2- to 3-fold higher and more consistent among primer sets when quantified using mtDNA primers rather than nuDNA primers, which showed primer-dependent variability in concentration. In each case, DNA concentration as quantified by real-time PCR did not differ among groups when classified by adenocarcinoma stage but differences between diagnosis were dependent on the gene used for quantification. Specifically, levels of the mtCYTB and mtNADI genes were comparable between all groups and levels of mtCOXIII were comparable between serum from patients with benign growths and trauma patients but higher in serum from patients with adenocarcinoma than those with benign growths or healthy controls (P<0.0001, both). In contrast, levels of the nuACTB were higher and nuSIRT1 lower in patients with benign growths than in healthy controls (P<0.01, both), but both nuACTB and nuSIRT1 levels were significantly higher in the serum of adenocarcinoma patients than serum from patients with benign growths (P<0.001 and P<0.0001, respectively) or trauma patients (P<0.0001 and P<0.05, respectively). Importantly, higher levels of nuACTB and mtCOXIII were found in the fresh serum from volunteers than adenocarcinoma patients. DNA concentration as measured by fluorometry was higher in serum from patients with adenocarcinoma than in serum from volunteers and resembled the DNA yield as determined by real-time PCR using mitochondrial gene-specific primers. The majority of the DNA in serum (90%) remained after incubation of serum with DNAse, indicating that the DNA is protected potentially by being localized in exosomes.  Greater than 90% of the mtDNA found in serum was found in the exosome pellet, confirming the association of the serum mtDNA with exosomes, but very little mtDNA was found in the supernatant. A much smaller amount of nuclear DNA was present and, like the mtDNA, was mostly associated with the exosomes. Compared to the serum of healthy controls, a higher amount of mtCOXIII and mtNADI were found in the serum of patients with mild (P<0.05, both) and severe traumatic brain injury (P<0.0001) but the nuclear DNAs, nuACTB, and nuSIRT1 were only significantly higher in the serum of patients with severe traumatic brain injury compared to healthy controls (P<0.01, both). Importantly, the DNA concentration as measured by PicoGreen mirrored the results for mtDNA with significantly higher DNA levels in serum from patients with mild (P<0.05) or severe traumatic brain injury (P<0.0001) than in serum from healthy volunteers.

  • Biospecimens

    FluidSerum
  • Preservation Types

    FrozenNone (Fresh)
  • Diagnoses

    Normal
    Other diagnoses
    NeoplasticCarcinoma
    NeoplasticBenign
  • Platforms

    DNAFluorometry
    DNAReal-time qPCR
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    Benign lung growth
    Healthy
    Lung adenocarcinoma
    Mild traumatic brain injury
    Severe traumatic brain injury
    PreaquisitionPrognostic factor
    Stage I
    Stage II
    Stage III
    Stage IV
    Biospecimen Aliquots and ComponentsBlood and blood products
    Serum
    Serum exosomes
    Serum supernatant
    Analyte Extraction and PurificationAnalyte isolation method
    Exosomes isolated
    No exosome isolation
    Analyte Extraction and PurificationNucleic acid digestion
    DNAse treated
    Not treated
    Real-time qPCR SpecificTargeted nucleic acid
    mtCOXIII
    mtCYTB
    mtNADI
    nuACTB
    nuSIRT1
    Real-time qPCR SpecificTechnology platform
    PicoGreen